Location of Repository

Topotecan given as a 21-day infusion in the treatment of advanced ovarian cancer

By M Gore, G Rustin, J Schüller, S R Lane, S Hearn, R A Beckman and G Ross

Abstract

A phase II programme was carried out in both Europe and North America to evaluate the activity of topotecan administered as a 21-day continuous intravenous infusion to patients with recurrent ovarian cancer. The European results are reported here. Patients who had failed first line therapy with a platinum-based regimen received topotecan 0.4 mg/m2/day, as a 21-day infusion every 28 days. Patients were only permitted one prior regimen. 35 patients were enrolled and evaluable for response. 3 patients (8.6%) had a partial response to treatment (95% CI 1.8%, 23.1%) with a median time to response of 8.1 weeks and a median duration of response of 17.6 weeks. Response was also evaluated by CA125 and was also found to be 8%. For all 35 patients, median time to progression was 16.1 weeks and median survival was 43.6 weeks. The principal toxicity was myelosuppression although grade 4 neutropenia occurred in only 8.8% of patients (2.1% of courses) and infectious complications were relatively infrequent. Non-haematological toxicity was generally mild and mainly consisted of gastrointestinal events, alopecia and fatigue. A prolonged infusion of topotecan was well tolerated with a low incidence of severe neutropenia. Responses were seen in both North American and European patients. Response rates varied between the 2 studies possibly due to differences in patient demographics. © 2001 Cancer Research Campaign http://www.bjcancer.co

Topics: Regular Article
Publisher: Nature Publishing Group
OAI identifier: oai:pubmedcentral.nih.gov:2363856
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • http://www.bjcancer.com (external link)
  • Suggested articles

    Preview

    Citations

    1. (1992). Improved therapeutic index of carboplatin plus cyclophosphamide vs cisplatin plus cyclophosphamide: final report by the Southwestern Oncology Group of a phase III randomised trial in stage III and IV ovarian cancer.
    2. (2000). Principles and Practice of Gynecologic Oncology, 2nd edition, pp 919–986.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.